Top Back to top

Outcomes of patients treated with Ibrutinib post autologous stem cell transplant for mantle cell lymphoma.

Study number:
Short title:
PT Ibrutinib for MCL
Study status:
data collection
Deadline for data collection:
Study design:
Retrospective EBMT registry based analysis.
Primary objective:
To evaluate the outcomes of patients with MCL who receive Ibrutinib for relapse following the current standard first line therapy in fit patients (Rituximab containing induction regimes and ASCT in first response).
Key inclusion criteria:
Inclusion Criteria
• Age≥18 years at diagnosis
• Histological diagnosis of mantle cell lymphoma (MCL)
• First Autologous stem cell transplant
• Induction immunochemotherapy with a rituximab containing regimen
• Achieved a CR or PR after 1 or 2 lines of induction treatment
• ASCT in first response (CR/PR 1)
• Relapse on or after 1st October 2014 (date of European licence grant for ibrutinib) and before January 2017

Exclusion criteria
• Not treated with ibrutinib for relapse after ASCT
Principal investigator:
Steve Robinson / Claire Burney
Principal investigator email:
EBMT Study coordinator:
Hervé Finel / Irma Khvedelidze
Study coordinator email:

Need help?

The personal data provided will be processed according to the General Data Protection Regulation (GDPR 2016/679 ) and incorporated to a file property of EBMT which will be allocated in the EEA (European Economic Area) or in countries that are provided with the same level of protection for privacy such as countries that adhere to EU-US and Swiss-US Privacy Shield Frameworks.
Data Subjects have the right of access to his or her data and the right to rectification of any inaccurate or incomplete personal data. The Data Subject also has the right to withdraw consent, this wish will be respected, and the personal will no longer be made available. If the processing operation is unlawful the Data Subject has the right to request deletion of that data. Please write to